Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Patient characteristics stratified by study period

From: Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer

Characteristic Period A (n= 151)* Period B (n= 123) P-value
  n (%) n %  
Median age, years 50   51   0.33
Histology      
 Inflammatory 25 (17) 27 (22)  
 Non-Inflammatory 126 (83) 96 (78) 0.59
Site of Metastasis      
 Liver 28 (19) 45 (37) 0.30
 Lung 45 (30) 39 (32) 0.24
 Brain 4 (3) 10 (8) 0.72
 Bone 84 (56) 82 (67) 0.008
 Bone Only 37 (25) 31 (25) 0.52
 Supraclavicular Node 55 (36) 34 (28) 0.20
 Soft tissue 20 (13) 22 (18) 0.18
ER Status      
 Positive 56 (63) 75 (68)  
 Negative 33 (37) 34 (32) 0.01
PR Status      
 Positive 43 (48) 54 (51)  
 Negative 45 (52) 53 (49) 0.75
HER2 Status      
 Positive 1 (50) 31 (39)  
 Negative 1 (50) 32 (62) 0.71
Receipt of Endocrine therapy      
 SERMs 82 (54) 52 (42) 0.0002
 AI 19 (13) 46 (37) 0.72
 LHRH 0 (0) 5 (4) 0.87
 Fulvestrant 2 (1) 19 (15) 0.86
Receipt of Chemotherapy      
 Category A** 85 (56) 15 (12)  
 Category A + B 32 (21) 95 (77) <0.0001
Receipt of HER2-directed therapy 2 (1) 19 (15) 0.17
Receipt of Bisphosphonates      
 Pamidronic acid 8 (5) 37 (30) 0.0007
 Zoledronic acid 3 (2) 35 (28) 0.04
  1. Percentages reflect the proportion of patients in each subgroup relative to the total number of patients in the respective period (i.e., Period A or Period B), except for ER, PR, and HER2 status. For these variables, percentages reflect the proportion of patients in each subgroup relative to the total number of patients in the respective period for whom pathologic data is available. P-values determined using the Chi-square test.
  2. * Period A encompasses patients diagnosed between January 1, 1985 and December 31, 1994. Period B encompasses patients diagnosed between January 1, 1995 and December 31, 2004.
  3. ** See Table 1 for delineation of cytotoxic agents within Category A and Category B.